Home / Weight & metabolism / Eloralintide
ElHuman trials

Eloralintide

Eloralintide is an experimental weekly injection from Eli Lilly that copies amylin, a hormone that helps you feel full. It is not approved anywhere yet. Phase 3 trials are running.

Not approved anywhere (investigational)Phase 2 done (263 adults, 48 weeks); phase 3 trials recruiting
OverviewDosingMixingResearchCommunitySafetyFAQSources

Eloralintide quick reference

TypeAmylin receptor agonist (peptide)
Studied forWeight loss
EvidencePhase 2 done, phase 3 running
RouteInjection under the skin
Half-lifeSupports weekly dosing

What is Eloralintide?

Weekly injection that copies the fullness hormone amylin.

Used for weight loss; people want strong results at one shot a week.

Not approved anywhere. Lilly phase 3 trials are recruiting.

How Eloralintide works

Amylin receptor

Switches on amylin receptors, which signal fullness.

Selective design

Favors the AMY1 receptor over calcitonin receptors (cell tests).

Smaller meals

In obese rats it cut food intake and mostly lowered fat.

Less taste aversion

Lean rats avoided food less than with cagrilintide.

What Eloralintide is studied for

PeopleWeight loss

Adults lost up to 20% of body weight in 48 weeks.

PeopleEarly dosing

12 weeks of fixed doses gave 2.6% to 11.3% loss.

PeopleAdd-on to tirzepatide

Phase 1 safety study finished; phase 3 combo planned.

PeopleKnee pain, sleep apnea

Phase 3 trials are recruiting.

AnimalsFood intake

Obese rats ate less and lost mostly fat.

Lab / cellsReceptor targeting

Cells responded most to the AMY1 receptor.

Eloralintide dosing protocol

Phase 2 groupWeekly amount (48 weeks in total)
Fixed1 mg, 3 mg, 6 mg or 9 mg the whole time
Step-up A6 mg for 20 weeks, then 9 mg for 28 weeks
Step-up B3 mg for 4 weeks, 6 mg for 4 weeks, then 9 mg for 40 weeks
RouteInjection under the skin, once a week

From the registry entry for NCT06230523 and the Lancet paper (Billings et al. 2025). This is a trial schedule, not a label. No dosing label exists yet.

TRIAL SCHEDULE3 mg x4 wk, 6 mg x4 wk, 9 mg x40 wkTrial
TRIAL FIXED DOSES1, 3, 6 or 9 mg weeklyTrial
TRIAL STEP-UP6 mg x20 wk, then 9 mg x28 wkTrial
COMMUNITY START500 mcg weeklyCommunity
COMMUNITY BUILD-UPSlow steps over many weeksCommunity

Label and trial amounts come from the sources below. Community amounts are what people report; they have not been tested.

Mixing

Vial10 mg
+
BAC water2 mL
=
Strength5 mg per mL

Common example. Add BAC water slowly, swirl, keep cold.

Open the peptide calculator

What the research found

Phase 2 trial, 263 adults with obesity or overweight, no diabetes, 48 weeks. Average change in body weight (efficacy estimand, which counts the effect when treatment is taken as planned):

-20.1%9 mg weekly
-17.6%6 mg weekly
-12.4%3 mg weekly
-0.4%Placebo

Billings LK et al. Lancet 2025 (DOI 10.1016/S0140-6736(25)02155-5); posted results at ClinicalTrials.gov NCT06230523. 1 mg gave -9.4%; the two step-up plans gave -19.9% (6 to 9 mg) and -16.5% (3, 6, then 9 mg).

Eloralintide community experience

What users report. Not tested in trials.

Positive reports

  • Quieter appetite Users describe smaller meals, not a stimulant feel.
  • Gentle feel Some say it feels smoother than GLP-1 drugs.
  • Phase 2 buzz Interest jumped after the 20% weight-loss result.

Negative & mixed

  • Nausea and tiredness Early fullness, nausea and fatigue come up often.
  • Unverified vials Most reports cannot confirm what was in the vial.
  • Hard to sort out Mixing with GLP-1 drugs blurs which drug did what.

Eloralintide stacking

Eloralintide + tirzepatide

Lilly ran a phase 1 safety study; phase 3 is planned.

Eloralintide + retatrutide

Not studied together.

Eloralintide + cagrilintide

Both hit amylin receptors. Not studied together.

Eloralintide side effects & safety

Common

  • Nausea: 64% on 6 mg, 33% on 9 mg, 14% placebo.
  • Fatigue: 43% on 9 mg, 12% on placebo.
  • Lower appetite: 19% in the 12-week phase 1.
  • Headache: 12% in phase 1.
  • Slow step-up (3, 6, 9 mg) had less nausea: 25%.

Less common

  • One serious event in phase 1, judged unrelated.
  • Long-term safety past 48 weeks is unknown.
  • No pregnancy data.

Precautions

  • Pregnancy or breastfeeding: no data.
  • Seek care for repeated vomiting or no fluids kept down.
  • Other weight or glucose drugs add effects; data is limited.
  • Vial identity and purity are unverified outside trials.

Our verdict on Eloralintide

Strong 48-week phase 2 weight loss. Phase 3 results and long-term safety are still pending.

Eloralintide FAQ

Is eloralintide approved?

No. Phase 3 trials are running.

How much weight did people lose?

Up to about 20% at 9 mg over 48 weeks.

How is it different from semaglutide?

It acts on amylin receptors, not GLP-1.

How often is it injected?

Once a week, under the skin.

Sources

  • Billings LK et al. Lancet 2025, 48-week phase 2 trial of eloralintide, NCT06230523 (abstract on PubMed 41207310)
  • ClinicalTrials.gov NCT06230523 (arms and posted results)
  • ClinicalTrials.gov NCT07321886 and NCT07392190 (phase 3 obesity trials, recruiting)
  • Review: Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides 2026
  • Eloralintide, a selective, long-acting amylin receptor agonist: phase 1 proof of concept. Diabetes Obes Metab 2026 (PubMed 41559929)
  • Eloralintide (LY3841136): from discovery to clinical proof of concept. Mol Metab 2025 (PubMed 41109426)
  • ClinicalTrials.gov NCT06916065 (eloralintide with tirzepatide, phase 1) and NCT07881432 (EloraTZP phase 3, not yet recruiting)